Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) [Phase 3]

View source ↗

Summary

This Phase 3 study evaluated pembrolizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 3 | Status: COMPLETED | Results posted: 2022-07-05